|
36-5250-2016-001 301 Non-Carrier
Janssen Alzheimer Immunotherapy Research and Development. Phase III multicenter randomized, double blind, placebo controlled parallel group. Carriers (302) and non-carriers (301)
Recruitment Closed
|
Janssen Al, |
Murman |
|
36-5250-2015-001 302 Carrier
Janssen Alzheimer Immunotherapy Research and Development. Phase III multicenter randomized, double blind, placebo controlled parallel group. Carriers (302) and non-carriers (301)
Recruitment Closed
|
Janssen Al, |
Murman |
|
36-5250-2021-001 Elan 351
Janssen A1 AAB-001 (bepineuzamab) open-label, together extension study in patients with mild to moderate Alzheimer's disease
Recruitment open
|
Janssen Al. |
Murman |
|
36-5250-2022-001 Pharmacoeconomic
Investigator Initial Janssen Al " Modeling the impact of dependency on pharmacoeconmic outcomes in Alzheimer's disease (Elan2)
Recruitment open
|
Janssen AI. |
Murman |
|
Prodromal
A Phase 3, Randomized, Double Blind, Placebo Controlled, Multicenter, Efficacy, and Safety Study of Bapineuzumab Administered Subcutaneously at
NEW Pending
|
Janssen AI |
Murman |
|
STEADY PD3
Safety, Tolerability, and Efficacy Assessment of Dynacirc CR for Parkinson’s Disease
NEW Pending
|
NIH sub-award with Univ Rochester |
Bertoni |
|
36-5250-2019-001 S187.3.004
Open-Label 12 Month Safety and Efficacy Study of Levodopa-Caridopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson's Disease and Severe Motor-Fluctuations Despite Optimized Treatment with Available Parkinson's Disease Medications
Recruitment closed
|
Solvay |
Bertoni |
|
36-5250-2020-001 ADAGIO
An Open-label, MultiCenter, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study
Recruitment closed
|
Teva |
Bertoni |
| Merck Serono, SA Safinamide Trial |
Merck Serono |
Bertoni |
| Open-Label 12 Month Safety and Efficacy Study of Levodopa-Caridopa Intestinal Gel in Levodopa-Responsive Parkinson's Disease Subjects |
Solvay |
Bertoni |
| A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments with Parkinson Medicinal Products, who Continue to Experience Persistent Motor Fluctuations |
Solvay |
Bertoni |
|
Progeni Family Study
Recruitment open
|
MJFF |
Bertoni |
|
36-5250-2024-001 S187.3.002
Recruitment closed
|
Solvay |
Bertoni |
|
36-5250-2027-001 S187.3.003
Recruitment closed
|
Solvay |
Bertoni |
|
36-5250-2023-001 PostCept
A Longitudinal Observational Follow-up of the PRECEPT Study Cohort
Recruitment closed
|
NIH/Univ of Rochester |
Bertoni |
|
DCVPF
Differentiation of Central vs Peripheral Fatigue in Parkinson’s Disease
New Pending
|
NIH Sub w/Creighton |
Bertoni |
|
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 5-Arm, Parallel-Group Trial to Assess Rotigotine Transdermal System Dose Response tin Subjects with Advanced -Stage Parkinson's Disease
Recruitment closed
|
Bertoni |
|
36-5250-2013-001 IRIS
Insulin Resistance Intervention after Stroke
Recruitment closed
|
NIH sub-award from Yale University |
Fayad |
|
36-5250-2012-001 RESPECT
The Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment
Recruitment closed
|
AGA Medical |
Fayad |
| Capture 2 Study --05-716 Carotid RX ACCULINK/ACCUNET Post -Approval Trial To Uncover Unanticipated and Rare Events |
Fayad |
|
|
AVF
Augmented Visual Feedback for Learning Movements in Unpredictable Environments: Behavioral and Brain Correlates in Stoke Patients
New Pending
|
NIH sub-award from UNL |
Fayad |
|
EVP
The Effect of Visual Perception of Self Motion on Locomotor Adaptation after Stroke
|
NIH sub-award from UNO |
Fayad |
|
Stem Cell Protocol # B01-02
Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem in Adults with Ischemic Stroke
New Pending
|
Athersys |
Fayad |
|
36-5250-2026-001 Stratify 2
JCV Antibody Program in Patients with Relapsing MS Receiving or Considering Treatment with Tysabri
Recruitment Open
|
Biogen |
Zabad |
|
OPERA
Randomized, Double-Blink, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy & Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif) in Patients with Relapsing MS
Recruitment Open
|
Roche |
Zabad |
|
ASCEND
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Patients with Secondary Progressive Multiple Sclerosis
Recruitment Open
|
Biogen |
Zabad |
|
The Role of Ancanthamoeba Castellani in the Pathophysiology of Multiple Sclerosis
Recruitment Open
|
UNL Dr Reddy |
Zabad |
|
NMR
Developing NMR Metabolomics as a Diagnostic Tool for Multiple Sclerosis & Pancreatic Cancer
Pending
|
NIH Subaward w/UNL |
Zabad |
|
BMI
Brain Mechanical Imaging for CNS
Pending
|
NIH Subaward w/UNL |
Zabad |
|
PoNS
Randomized Clinical Trial for the PoNS that will be Performed at UNMC
Pending
|
In design stage |
Zabad |
|
COSMOS
Multicenter ALS Cohort Study of Oxidative Stress & Disease Progression
Pending
|
NIH/NIEHS & MS Association w/Columbia University |
Fernandes |
|
36-5250-2029-001 Rasagiline
A Multi-Center Screening Trial of Safety & Efficacy of Rasagiline in Subjects with Amyotrophic Lateral Sclerosis (Rasagiline)
Recruitment Open
|
UKMC & Western ALS Study Group |
Fernandes |
|
NEALS
The Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) Reliability Studies: Outcome Measures in Amyotrophic Lateral Sclerosis Research
|
NEALS |
Fernandes |
